Soleno Therapeutics Inc
6XC
Company Profile
Business description
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
Contact
100 Marine Parkway
Suite 400
Redwood CityCA94065
USAT: +1 650 213-8444
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
133
Stocks News & Analysis
stocks
Nvidia: Collaboration with Intel might bring some goodwill with the US
We doubt the $5 billion is meaningful enough to force Nvidia to use Intel, either for core products or even for the chips in collaboration.
stocks
What now for Santos after takeover offer collapses?
Our Fair Value estimate once again reflects the stand-alone business and its growth potential.
stocks
Morningstar initiates coverage on small cap ASX REIT
Coverage of ASX listed REIT as investor interest in property continues to grow.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,094.10 | 12.40 | 0.14% |
| CAC 40 | 7,854.61 | 67.63 | 0.87% |
| DAX 40 | 23,674.53 | 315.35 | 1.35% |
| Dow JONES (US) | 46,142.42 | 124.10 | 0.27% |
| FTSE 100 | 9,228.11 | 19.74 | 0.21% |
| HKSE | 26,535.35 | 9.50 | -0.04% |
| NASDAQ | 22,470.72 | 209.40 | 0.94% |
| Nikkei 225 | 45,183.78 | 119.65 | -0.26% |
| NZX 50 Index | 13,231.66 | 111.63 | 0.85% |
| S&P 500 | 6,631.96 | 31.61 | 0.48% |
| S&P/ASX 200 | 8,806.60 | 14.40 | 0.16% |
| SSE Composite Index | 3,837.01 | 5.35 | 0.14% |